Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
Date:6/8/2012

THOUSAND OAKS, Calif., June 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar®/Mimpara® (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis. The primary endpoint of the study was time to the composite event comprising all-cause mortality or first non-fatal cardiovascular event, including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event. Although patients in the Sensipar/Mimpara arm experienced numerically fewer composite primary events, the results were not statistically significant, and the trial did not meet its primary endpoint in the intent-to-treat analysis.

"Amgen embarked on the EVOLVE trial to understand whether treating secondary HPT with Sensipar/Mimpara could positively impact the high rates of mortality and cardiovascular events among patients with CKD receiving dialysis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We thank the patients, caregivers and investigators for their participation and engagement in this landmark trial. EVOLVE will provide the nephrology community with important information."

The most frequently reported adverse events in the Sensipar/Mimpara arm of the trial were consistent with the known safety profile of this therapy and included nausea, vomiting and hypocalcemia.

Detailed efficacy and safety analyses from this landmark study are ongoing and will be submitted for presentation at a major medical meeting later this year.

Sensipar/Mimpara is an oral calcimimetic agent approved for the treatment of s
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
2. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
3. Amgen to Present at the Baird Growth Stock Conference
4. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
5. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
6. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
7. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
10. ERT Announces Clearance from German Federal Cartel Office
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  BioPharmX Corporation (NYSE MKT: BPMX) today announced the ... 3,636,364 shares of its common stock at a price ... granted the underwriters a 30-day option to purchase up ... public offering price. In addition, Korea Investment ... agreed to purchase 1,081,081 shares of common stock from ...
(Date:7/1/2015)... SAN FRANCISCO , July 1, 2015 ... health market) is expected to reach USD 49,119.2 million ... View Research, Inc. Monitoring services is expected to remain ... revenue of USD 1,227.5 million in 2012, and an ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:7/1/2015)... , July 1, 2015 ... its Executive Board. Mr. Gert Weber has ... Invest AG as Chief Executive Officer (CEO) ... July 1 st , 2015. Mr. Weber brings more ... technological industries and has filled various executive management positions, ...
Breaking Medicine Technology:BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:7/1/2015)... ... 2015 , ... DIC Corporation today announced the on-schedule completion ... food coloring. Construction of the plant, which is located on the site of ... May 2014. After commissioning, commercial production is expected to begin in September. A ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... The ... from the New York Community Trust. The grant will allow CCF to improve quality ... proven practices. , CCF was formed to respond to many changes in New York’s ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Hospital Corporation of America (HCA), as it further expands its Strategic Alliance ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate ...
(Date:7/1/2015)... ... July 01, 2015 , ... During the first week of ... Training and Development) and Chuck Corso (Associate Sales Trainer) participated in the 44th ... brings together learning and development professionals from more than 300 life sciences companies ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted by ... 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will ... zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders from ...
Breaking Medicine News(10 mins):Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4
... Could some of the natural chemicals found in ... Researchers at Wake Forest University Baptist Medical Center ... the potential cardiovascular health effects of Natures Pearl ... evaluating the influence of this supplement on blood ...
... Mich., Oct. 24 Creative Technology Services, ... a new operating business,unit, NEXT Mobility, LLC ... products. Next Mobility will speed CTS, growth ... rehabilitation and durable medical,equipment businesses in a ...
... way to use a simple blood test that may ... warning and is almost always fatal if untreated. , ... Science (PLoS), represents the collaborative work of Yale School ... occur in the part of the aorta that passes ...
... Advanced Disease, ROCKVILLE, Md., Oct. 24 ... company developing,therapeutics for the treatment of cancer and ... its Phase 2, open-label study for,Panzem(R) NCD (2ME2 ... were presented by Dr. Daniela Matei, principal investigator ...
... Snipping away excess tissue helps, study finds , WEDNESDAY, ... excess tissue in the throat or mouth to widen ... apnea, a U.S. study finds. , Researchers followed 63 ... found that the procedure, called uvulopalatopharyngoplasty (UPPP), eliminated obstructive ...
... urgency and insight into the growing nursing shortage ... ... and hospital employees,report better compensation, staffing levels, and recognition for work ... 2007 Hospital,Check-Up Report: Nurse and Employee Perspectives on American Health Care.,The ...
Cached Medicine News:Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 2Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 3Health News:Creative Technology Services Creates a New Operating Company Focused on Mobility 2Health News:A new key to detecting deadly aortic aneurysms 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 3Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 4Health News:Surgery Can Cut Sleep Apnea 2Health News:Nurses and Hospital Employees' Top Concerns: Communication, Staffing and Compensation 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: